Adrenocortical carcinoma. Diagnostic work-up and treatment;Das nebennierenkarzinom. Diagnostik und therapie

Urologe - Ausgabe A

Volumn 47, Issue 2, 2008, Pages 172-181

  Johanssen, S ^a   Fassnacht, M ^a   Brix, D ^a   Koschker, A C ^a   Hahner, S ^a   Riedmiller, H ^a   Allolio, B ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Adrenal imaging; FIRM ACT study; Hormonal work up; Mitotane; Open adrenalectomy

Indexed keywords

CISPLATIN; CONTRAST MEDIUM; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HORMONE; HYDROCORTISONE; MITOTANE; STREPTOZOCIN; SUNITINIB;

ADRENAL BIOPSY; ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; CANCER CHEMOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FAT CONTENT; FOLLOW UP; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIOPERATIVE PERIOD; PEROPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; SPILLAGE; SURGICAL TECHNIQUE; TUMOR RECURRENCE;

EID: 43149083274     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-007-1578-0     Document Type: Review

References (28)

1. 1. Abraham 2002 Cancer 94 2333 12015757 10.1002/cncr.10487 1:CAS:528:DC%2BD38XktF2hs7Y%3D Abraham J, Bakke S, Rutt A et al. (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristin, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94(9): 2333–2343
2. 2. Allolio 2006 J Clin Endocrinol Metab 91 2027 16551738 10.1210/jc.2005-2639 1:CAS:528:DC%2BD28XlvVCgsr4%3D Allolio B, Fassnacht M (2006) Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91(6): 2027–2037
3. 3. Barzon 1999 J Clin Endocrinol Metab 84 520 10022410 10.1210/jc.84.2.520 1:STN:280:DyaK1M7ksFSjug%3D%3D Barzon L, Scaroni C, Sonino N et al. (1999) Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 84: 520–526
4. 4. Berruti 2005 Endocr Relat Cancer 12 657 16172198 10.1677/erc.1.01025 1:CAS:528:DC%2BD2MXht1SjsrrN Berruti A, Terzolo M, Sperone P et al. (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12: 657–666
5. 5. Boland 1998 AJR Am J Roentgenol 171 201 9648789 1:STN:280:DyaK1czhtFWhsQ%3D%3D Boland GW, Lee MJ, Gazelle GS et al. (1998) Characterization of adrenal masses in unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 171(1): 201–204
6. 6. Bonacci 1998 Br J Cancer 78 546 9716042 1:CAS:528:DyaK1cXlslWjurc%3D Bonacci R, Gigliotti A, Baudin E et al. (1998) Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM. Br J Cancer 78(4): 546–549
7. 7. Bukowski 1993 J Clin Oncol 11 161 8418229 1:STN:280:DyaK3s7hsFOltA%3D%3D Bukowski RM, Wolfe M, Levine HS et al. (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma. J Clin Oncol 11(1): 161–165
8. 8. Decker 1991 Surgery 110 1006 1745969 1:STN:280:DyaK38%2FotV2rtw%3D%3D Decker RA, Elson P, Hogan TF et al. (1991) Eastern Cooperative Oncology Group Study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110(6): 1006–1013
9. 9. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France; IARC Press
10. 10. Fassnacht 2006 Exp Clin Endocrinol Diabet 114 17 Fassnacht M, Hahner S, Polat B et al. (2006) Adjuvant radiation therapy of the tumor bed prevents local recurrences in adrenocortical carcinoma. Exp Clin Endocrinol Diabet 114(Suppl 1): 17
11. 11. Fassnacht 2004 J Endocrinol Invest 27 387 15233562 1:STN:280:DC%2BD2czjtFamtA%3D%3D Fassnacht M, Kenn W, Allolio B (2004) Adrenal tumors: how to establish malignancy? J Endocrinol Invest 27: 387–399
12. 12. Grumbach 2003 Ann Intern Med 138 424 12614096 Grumbach MM, Biller BM, Braunstein GD et al. (2003) Management of the clinically inapparent adrenal mass („incidentaloma“). Ann Intern Med 138: 424–429
13. 13. Hahner 2005 Curr Opin Investig Drugs 6 386 15898346 1:CAS:528:DC%2BD2MXktF2gsbw%3D Hahner S, Fassnacht M (2005) Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6: 386–394
14. 14. Hennings 2006 J Clin Endocrinol Metab 91 1410 16403816 10.1210/jc.2005-2273 1:CAS:528:DC%2BD28XjvFOktr8%3D Hennings J, Lindhe Ö, Bergström M et al. (2006) [11C]Metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91: 1410–1414
15. 15. Honigschnabl 2002 Eur J Radiol 41 113 11809540 10.1016/S0720-048X(01)00443-0 Honigschnabl S, Gallo S, Niederle B et al. (2002) How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study. Eur J Radiol 41:113–122
16. 16. Khan 2000 Ann Oncol 11 1281 11106117 10.1023/A:1008377915129 1:STN:280:DC%2BD3MzgsVKltw%3D%3D Khan TS, Imam H, Juhlin C et al. (2000) Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11:1281–1287
17. 17. Kirschner 2006 J Clin Endocrinol Metab 91 14 16234301 10.1210/jc.2005-1739 1:CAS:528:DC%2BD28Xms1aitw%3D%3D Kirschner LS (2006) Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 91: 14–21
18. 18. Koschker 2006 Exp Clin Endocrinol Diab 114 45 10.1055/s-2006-923808 1:CAS:528:DC%2BD28Xjslylur8%3D Koschker AC, Fassnacht M, Hahner S et al. (2006) Adrenocortical carcinoma: Improving patient care by establishing new structures. Exp Clin Endocrinol Diab 114(45): 45–51
19. 19. Leboulleux 2006 J Clin Endocrinol Metab 91 920 16368753 10.1210/jc.2005-1540 1:CAS:528:DC%2BD28Xis1CmtL4%3D Leboulleux S, Dromain G, Bonniaud G et al. (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91: 920–925
20. 20. Lee 1995 Surgery 118 1090 7491528 10.1016/S0039-6060(05)80119-9 1:STN:280:DyaK28%2FovFShtQ%3D%3D Lee JE, Berger DH, el-Naggar AK et al. (1995) Surcigal management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118: 1090–1098
21. 21. NCI (1981) Surveillance, epidemiology and end results: incidence and mortality data 1973-77. Bethesda, Maryland, National Cancer Institute
22. 22. Saeger 2000 Eur J Clin Invest 30 58 11281370 10.1046/j.1365-2362.2000.0300s3058.x Saeger W (2000) Histopathological classification of adrenal tumours. Eur J Clin Invest 30(Suppl 3): 58–62
23. 23. Schlumberger 1991 Cancer 67 2997 2044046 10.1002/1097-0142(19910615)67:12<2997::AID-CNCR2820671211>3.0.CO;2-# 1:STN:280:DyaK3M3ls1Wnsg%3D%3D Schlumberger M, Brugieres L, Gicquel C et al. (1991) 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67(12): 2997–3000
24. 24. Schteingart 2005 Endocr Relat Cancer 12 667 16172199 10.1677/erc.1.01029 1:STN:280:DC%2BD2MrgtVWqsg%3D%3D Schteingart DE, Doherty GM, Gauger PG et al. (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12: 667–680
25. 25. Terzolo 2007 N Engl J Med 356 2372 17554118 10.1056/NEJMoa063360 1:CAS:528:DC%2BD2sXmt1WnsLg%3D Terzolo M, Angeli, A, Fassnacht M et al. (2007) Adjuvant mitotane treatment in patients with adrenocortical carcinoma. N Engl J Med 356(23): 2372–2380
26. 26. van 1983 Cancer Treat Rep 67 377 van Slooten H, van Oosterom AT (1983) CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 67(4): 377–379
27. 27. Weiss 1989 Am J Surg Pathol 13 202 2919718 1:STN:280:DyaL1M7kvVGntg%3D%3D 10.1097/00000478-198903000-00004 Weiss LM, Medeiros LJ, Vickery AL Jr. (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13(3): 202–206
28. 28. Williamson 2000 Cancer 88 1159 10699907 10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R 1:CAS:528:DC%2BD3cXhvFGhsLo%3D Williamson SK, Lew D, Miller GJ et al. (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A Southwest Oncology Group Study. Cancer 88(5): 1159–1165